Powered by
-
AZN Stock Chart
Historical AZN Prices
Astrazeneca Plc Stock Analysis
Rating: Hold
Total Grade: C
Analysis Breakdown
| AZN Stock Grade: | C |
| Fundamental Grade: | C |
| Quantitative Grade: | B |
| AZN Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | B |
| Earnings Surprises: | C |
| Analyst Earnings Revisions: | C |
| AZN Financial Information | |
| Sales Growth: | D |
| Operating Margin Growth: | D |
| Cash Flow: | D |
| Return on Equity: | A |
Astrazeneca Plc Stock: Weekly View
| This Week: | C |
|---|---|
| Last Week: | B |
| Two Weeks Ago: | B |
AZN Stock predictions, Articles, and Astrazeneca Plc News
- From InvestorPlace
- From the Web
-
The 5 Best Dow Jones Stocks to Buy Now - October 2, 2018
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2018. Continue…
-
The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger - September 12, 2018
AstraZeneca's profits are poised to accelerate, but investors should wait for AZN stock to break out of its range before buying the shares. Continue…
-
Biogen Is the Right Alzheimer’s Stock … At the Wrong Time - July 10, 2018
BIIB stock jumped on Friday, and for good reason. It's not a buy at these lofty levels, but Biogen has at least earned a spot on your watchlist. Continue…
-
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry - June 14, 2018
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well. Compare Brokers.... Continue…
-
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - May 18, 2018
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are. Continue…
-
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales - May 18, 2018
AstraZeneca plc (AZN) stock was down on Friday following the release of its earnings report for the first quarter of 2018. Continue…
-
3 Emerging Technologies Set to Transform the Pharma World - April 5, 2018
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by.... Continue…
-
The Future of Merck & Co., Inc. Stock Is With Keytruda - February 5, 2018
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now. Continue…
-
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy - December 1, 2017
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month. Continue…
-
Earnings Visibility Make AstraZeneca (AZN) a Buy - November 17, 2017
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe. Continue…
